Imaging AI Moves From Detection to Capacity Control – May 22, 2026
A light approval week revealed a sharper market signal: imaging AI is being judged by its ability to protect constrained clinical pathways. 🎧 Listen to this week’s Marketstrat Pulse Insight: A narrow approval week with a broad operating signal The week ending May 22, 2026, did not produce a flood of new imaging AI approvals. […]
Imaging AI’s Operating Stack Moves From Model Proof to Capacity Control – May 15, 2026
GE, Siemens, RadNet, Fujifilm, AGFA, Viz.ai, Lumexa, and CMS show how imaging value is moving into uptime, workflow, authorization, and utilization economics. The most important imaging AI signals this week were not isolated algorithms. They were operating-stack signals. MRI uptime, interventional acquisition, outpatient slot capacity, enterprise imaging, prior authorization, and procedure workflow all moved into […]
Imaging AI Enters Its Operating Era – May 8, 2026
Roche/PathAI, ACR/SIIM governance, Siemens and Philips earnings, CMS prior-auth digitization, and new workflow clearances show imaging value moving beyond model performance. Imaging AI’s next phase is less about proving algorithms and more about governing, monitoring, integrating, and monetizing them inside clinical workflow. This week’s Marketstrat Pulse highlights five signals: Roche’s PathAI acquisition, the ACR/SIIM AI […]
Imaging AI’s New Moat Is Workflow Control – May 1, 2026
Capital, OEM strategy, provider consolidation, and procedural imaging are shifting the market from point algorithms to operating platforms. 🎧 Listen to this week’s Marketstrat Pulse Insight: This week’s Marketstrat | Pulse Insights points to a sharper imaging AI market. Aidoc’s $150 million financing, GE HealthCare’s Advanced Imaging Solutions reorganization, RadNet’s Idaho imaging joint venture, Abbott’s […]
Imaging AI’s New Moat: Coverage Speed, Workflow Control, and Evidence That Actually Moves Operations – April 24, 2026
This week’s medical imaging AI signal was not another model launch. It was the market moving toward reimbursable, governed, and routed workflow infrastructure. 🎧 Listen to this week’s Marketstrat Pulse Insight: The medical imaging AI market is entering a more disciplined phase. For the past several years, the category has been defined by algorithm count, […]
Marketstrat Receives USPTO Registration for Markintel® Service Mark
Registration reinforces Marketstrat’s commitment to building a structured market intelligence system for MedTech, medical imaging, imaging AI, and adjacent healthcare technology markets. SACRAMENTO, Calif. — Apr. 28, 2026 — Marketstrat Inc. announced today that the United States Patent and Trademark Office has registered Markintel® as a service mark of Marketstrat Inc. The registration marks an […]
Sectra Completes Oxipit Acquisition (2026-04-15)
Sectra / Oxipit — Market Signals | Marketstrat Marketstrat|Market Signals Deal Intelligence · MedTech Event-Driven Analysis No. 02 · April 2026 M&A · Radiology AI · EU → EU Sectra pulls autonomous AI inside the enterprise imaging stack. Completion of the Oxipit acquisition consolidates the independent autonomous chest X-ray AI market into two platforms in […]
Owned Workflow Gets Paid: Imaging AI Reimbursement, Spectral CT, PACS-AI Consolidation, and Image-Guided MIS
Reimbursable chest-CT AI, modality-native software, and platform ownership shift value from model novelty to monetized workflow control. Marketstrat® Pulse Insights | Week ending April 17, 2026Coverage: Medical Imaging AI | Enterprise Imaging IT | Imaging Reimbursement | AI-Enabled MedTech | Image-Guided MIS 🎧 Listen to this week’s Marketstrat Pulse Insight: If the April 10 week […]
Neuropacs De Novo: First FDA-Authorized AI Pathway for Chronic Neurodegenerative Disease Differentiation
Event Date: April 3, 2026 (FDA decision) | April 7, 2026 (public announcement) Marketstrat® · Markintel Market Signals Neuropacs De Novo: First FDA-Authorized AI Pathway for Chronic Neurodegenerative Disease Differentiation Published: April 16, 2026 Sector: MedTech & Digital Health Focus: Neurological Imaging AI FDA grants De Novo classification to neuropacs™ (April 3, 2026) Creates a […]
Routability Becomes the Moat – April 10, 2026
Prior authorization reform, workflow control, and provider-scale validation re-rank imaging AI KEY TAKEAWAYS COMMERCIALIZATION SURFACE MAP The Commercialization Surface Map explains where this week’s value sat. It plots the major signals by deployment-surface control and clinical or regulatory novelty, with bubble size reflecting strategic impact. The pattern is the story: the strongest signals clustered where […]
